Report error Found 190 with Last Name = 'wauwe' and Initial = 'jv'
TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataKi: 10nMAssay Description:Displacement of [125I]C5a from human recombinant C5a receptor in U937 cellsMore data for this Ligand-Target Pair
TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataKi: 13nMAssay Description:Displacement of [125I]C5a from human recombinant C5a receptor in U937 cellsMore data for this Ligand-Target Pair
TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataKi: 21nMAssay Description:Displacement of [125I]C5a from human recombinant C5a receptor in U937 cellsMore data for this Ligand-Target Pair
TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataKi: 680nMAssay Description:Displacement of [125I]C5a from human recombinant C5a receptor in U937 cellsMore data for this Ligand-Target Pair
TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 7nMAssay Description:Antagonist activity at human recombinant C5a receptor in U937 cells assessed as inhibition of C5a-induced calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 22nMAssay Description:Antagonist activity at human recombinant C5a receptor in U937 cells assessed as inhibition of C5a-induced calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 26nMAssay Description:Antagonist activity at human recombinant C5a receptor in U937 cells assessed as inhibition of C5a-induced calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 30nMAssay Description:Antagonist activity at human recombinant C5a receptor in U937 cells assessed as inhibition of C5a-induced calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 53nMAssay Description:Antagonist activity at human recombinant C5a receptor in U937 cells assessed as inhibition of C5a-induced calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
Affinity DataIC50: 60nMAssay Description:Antagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ...More data for this Ligand-Target Pair
Affinity DataIC50: 60nMAssay Description:Antagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ...More data for this Ligand-Target Pair
Affinity DataIC50: 60nMAssay Description:Antagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ...More data for this Ligand-Target Pair
TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 71nMAssay Description:Antagonist activity at human recombinant C5a receptor in U937 cells assessed as inhibition of C5a-induced calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
Affinity DataIC50: 80nMAssay Description:Antagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ...More data for this Ligand-Target Pair
Affinity DataIC50: 80nMAssay Description:Antagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ...More data for this Ligand-Target Pair
Affinity DataIC50: 120nMAssay Description:Antagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ...More data for this Ligand-Target Pair
Affinity DataIC50: 120nMAssay Description:Antagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ...More data for this Ligand-Target Pair
TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 120nMAssay Description:Antagonist activity at human recombinant C5a receptor in U937 cells assessed as inhibition of C5a-induced calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 140nMAssay Description:Antagonist activity at human recombinant C5a receptor in U937 cells assessed as inhibition of C5a-induced calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
Affinity DataIC50: 140nMAssay Description:Antagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ...More data for this Ligand-Target Pair
Affinity DataIC50: 140nMAssay Description:Antagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ...More data for this Ligand-Target Pair
Affinity DataIC50: 150nMAssay Description:Antagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ...More data for this Ligand-Target Pair
Affinity DataIC50: 170nMAssay Description:Antagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ...More data for this Ligand-Target Pair
Affinity DataIC50: 180nMAssay Description:Antagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ...More data for this Ligand-Target Pair
Affinity DataIC50: 210nMAssay Description:Antagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ...More data for this Ligand-Target Pair
Affinity DataIC50: 250nMAssay Description:Antagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ...More data for this Ligand-Target Pair
Affinity DataIC50: 290nMAssay Description:Antagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ...More data for this Ligand-Target Pair
TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 290nMAssay Description:Antagonist activity at human recombinant C5a receptor in U937 cells assessed as inhibition of C5a-induced calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
Affinity DataIC50: 320nMAssay Description:Antagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ...More data for this Ligand-Target Pair
Affinity DataIC50: 320nMAssay Description:Antagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ...More data for this Ligand-Target Pair
Affinity DataIC50: 330nMAssay Description:Displacement of [125I]ITAC from CXCR3 in PHA/IL-2 activated human PBMC pretreated 30 mins before [125I]ITAC challenge after 1 hr by liquid scintillat...More data for this Ligand-Target Pair
Affinity DataIC50: 330nMAssay Description:Antagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ...More data for this Ligand-Target Pair
TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 340nMAssay Description:Antagonist activity at human recombinant C5a receptor in U937 cells assessed as inhibition of C5a-induced calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
Affinity DataIC50: 340nMAssay Description:Antagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ...More data for this Ligand-Target Pair
TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 380nMAssay Description:Antagonist activity at human recombinant C5a receptor in U937 cells assessed as inhibition of C5a-induced calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 410nMAssay Description:Antagonist activity at human recombinant C5a receptor in U937 cells assessed as inhibition of C5a-induced calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 420nMAssay Description:Antagonist activity at human recombinant C5a receptor in U937 cells assessed as inhibition of C5a-induced calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 430nMAssay Description:Antagonist activity at human recombinant C5a receptor in U937 cells assessed as inhibition of C5a-induced calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
Affinity DataIC50: 500nMAssay Description:Antagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ...More data for this Ligand-Target Pair
Affinity DataIC50: 500nMAssay Description:Antagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ...More data for this Ligand-Target Pair
TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 560nMAssay Description:Antagonist activity at human recombinant C5a receptor in U937 cells assessed as inhibition of C5a-induced calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
Affinity DataIC50: 610nMAssay Description:Antagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ...More data for this Ligand-Target Pair
Affinity DataIC50: 630nMAssay Description:Antagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ...More data for this Ligand-Target Pair
Affinity DataIC50: 630nMAssay Description:Antagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ...More data for this Ligand-Target Pair
Affinity DataIC50: 690nMAssay Description:Antagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ...More data for this Ligand-Target Pair
TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 690nMAssay Description:Antagonist activity at human recombinant C5a receptor in U937 cells assessed as inhibition of C5a-induced calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 730nMAssay Description:Antagonist activity at human recombinant C5a receptor in U937 cells assessed as inhibition of C5a-induced calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
Affinity DataIC50: 780nMAssay Description:Antagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ...More data for this Ligand-Target Pair
Affinity DataIC50: 780nMAssay Description:Antagonist activity at human CXCR3 expressed in CHO cells assessed as inhibition of ITAC-stimulated [35S]GTPgammaS binding pretreated 30 mins before ...More data for this Ligand-Target Pair
TargetC5a anaphylatoxin chemotactic receptor 1(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 790nMAssay Description:Antagonist activity at human recombinant C5a receptor in U937 cells assessed as inhibition of C5a-induced calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair